-
London
Education
Summary
Dr. Fillbrunn specializes in health economics and outcomes research (HEOR), biostatistics, and epidemiology. His expertise includes strategically developing and guiding the implementation of analytics throughout the entire product life cycle, including analyses of clinical trials and real-world health care data such as insurance claims, electronic health records, medical charts, and surveys. Dr. Fillbrunn’s contributions have informed clinical regulators and health care payers in both the US and global markets. His research has been published in several peer-reviewed journals and presented at clinical and health economic conferences. Prior to joining Analysis Group, Dr. Fillbrunn was a postdoctoral fellow at Harvard Medical School and Massachusetts General Hospital.
Selected Cases & Publications
Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab: A US claims analysis
Journal of Allergy and Clinical Immunology: Global, 2025
Associated People
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma & Leukemia, 2025
Associated People
Transfusion-Related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials
Cancers, 2024
Associated People
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM
Future Oncology, 2024
Associated People
Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials
PLOS One, 2024
Associated People
Benefits of Autoantibody Enrichment in Early Rheumatoid arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials
Rheumatology and Therapy, 2023
Associated People
Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial
Open Forum Infectious Diseases, 2023
Associated People
Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study
Patient Preference and Adherence, 2022
Associated People
PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
BMC Cancer, 2022
Associated People
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
Cancers (Basel), 2022
Associated People